Strong antileukemic effect of chronic graft-versus-host disease in allogeneic marrow transplant recipients having acute leukemia treated with methotrexate and cyclosporine. The Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

Transplant Proc. 1997 Feb-Mar;29(1-2):733-4. doi: 10.1016/s0041-1345(96)00443-5.

Authors

O Ringdén¹, M Labopin, E Gluckman, J Reiffers, J P Vernant, J P Jouet, J L Harousseau, D Fiere, A Bacigalupo, F Frassoni, N C Gorin

Affiliation

¹ Department of Clinical Immunology, Huddinge Hospital, Stockholm, Sweden.

PMID: 9123501
DOI: 10.1016/s0041-1345(96)00443-5

No abstract available

Publication types

Comparative Study
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Acute Disease
Bone Marrow Transplantation*
Chronic Disease
Confidence Intervals
Cyclosporine / therapeutic use*
Female
Graft vs Host Disease / physiopathology*
Humans
Immunosuppressive Agents / therapeutic use*
Leukemia, Myeloid, Acute / therapy*
Male
Methotrexate / therapeutic use*
Multivariate Analysis
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
Probability
Recurrence
Retrospective Studies
Transplantation, Homologous

Substances

Immunosuppressive Agents
Cyclosporine
Methotrexate